Chao Chung Lin

US Patent:

7858383, Dec 28, 2010

Filed:

May 2, 2007

Appl. No.:

11/743576

Inventors:

Huarui He - Alpharetta GA, US
Chao Lin - Alpharetta GA, US
Neeta Raje - Alpharetta GA, US
Chusheng Liu - Atlanta GA, US

Assignee:

Opti Medical Systems - Westbrook ME

International Classification:

G01N 21/75

US Classification:

436166, 540467

Abstract:

The invention relates to methods of determining sodium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the sodium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

US Patent:

7960181, Jun 14, 2011

Filed:

May 2, 2007

Appl. No.:

11/743569

Inventors:

Huarui He - Alpharetta GA, US
Chao Lin - Alpharetta GA, US
Neeta Raje - Alpharetta GA, US
Chuseng Liu - Atlanta GA, US

Assignee:

OPTI Medical Systems - Westbrook ME

International Classification:

C07D 245/00
C07D 245/04
C07D 245/06
C07D 487/00

US Classification:

436166, 540470, 540471

Abstract:

The invention relates to methods of determining potassium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the potassium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

US Patent:

8158259, Apr 17, 2012

Filed:

Dec 6, 2007

Appl. No.:

11/987984

Inventors:

Narayanan Ramamurthy - Alpharetta GA, US
Huarui He - Alpharetta GA, US
Chao Lin - Alpharetta GA, US

Assignee:

Opti Medical Systems - Roswell GA

International Classification:

B32B 9/04
B32B 3/10
B05D 5/00

US Classification:

4284111, 4273722, 427402, 428131

Abstract:

The invention is directed to optical sensors for measuring clinically relevant analytes, their methods of manufacture, and their various uses. In an effort to develop a dry calibration method for the optical sensors of the invention it is discovered that water content inside or in the immediate vicinity of a such a sensor can have a major impact on fluorescence intensity (i. e. , a sensor's response in the dry state). Thus, one of the objectives of the invention is the elimination of the bias of sensor responses measured at different humidity environments.

US Patent:

20070259438, Nov 8, 2007

Filed:

May 2, 2007

Appl. No.:

11/743571

Inventors:

Huarui HE - Alpharetta GA, US
Chao LIN - Alpharetta GA, US

International Classification:

G01N 33/20
C07C 245/08

US Classification:

436080000, 534848000

Abstract:

The invention relates to methods of determining calcium ions in a sample, wherein the ions are contacted with a compound having chromophoric moiety and an ionophoric moiety, where the ionophoric moiety interacts with the calcium ions present in the sample, resulting in the chromophoric moiety changing its radiation absorption properties in the ultraviolet and visible regions of the spectrum. For example, a change in an intensity of an absorption maximum is measured and the ion concentration is determined accordingly.

US Patent:

20120183984, Jul 19, 2012

Filed:

Jul 22, 2010

Appl. No.:

13/386021

Inventors:

Huarui He - Alpharetta GA, US
Chao Lin - San Diego CA, US

Assignee:

OPTI MEDICAL SYSTEMS - Westbrook ME

International Classification:

G01N 21/76
C07D 401/12
C08B 15/06
C07D 311/82
C07C 217/20
C07C 323/25
C07F 5/02
C07D 221/14
C07C 217/84

US Classification:

435 28, 546100, 536 31, 564370, 564354, 564341, 564367, 564353, 548405, 549394, 436135

Abstract:

The invention provides compounds of formula I F-L-Q (I) where F comprises a fluorophore capable of absorbing energy at an excitation wavelength and, in the absence of a quencher, emitting energy at an emission wavelength, which is different than the excitation wavelength; Q comprises a quencher; L comprises a linker moiety having two ends, one end being covalently bound to F and the other end being covalently bound to Q. The compounds are capable of undergoing a reversible reaction (1), provided below: (1) where Q is an oxidized form of Q representing the absence of a quencher, Ox comprises an oxidizing agent, which is capable of oxidizing Q to its oxidized form Q, and Red comprises a reducing agent, which is capable of converting Q back to its reduced form Q. The compounds can undergo photo-induced electron transfer when irradiated with energy and when Q exists in its oxidized form, Q. The invention also provides methods of detecting and determining the presence of analytes and/or hydrogen peroxide in a sample, as well as a substrate that comprises the compound of formula I.

US Patent:

20190151314, May 23, 2019

Filed:

Jun 25, 2018

Appl. No.:

16/016917

Inventors:

- Boston MA, US
Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Randy S. Bethiel - Lexington MA, US
John J. Court - Littleton MA, US
Hongbo Deng - Wellesley MA, US
loana Davies - Arlington MA, US
John P. Duffy - Northborough MA, US
Luc J. Farmer - Montreal, CA
Huai Gao - Arlington MA, US
Wenxin Gu - Concord MA, US
Dylan H. Jacobs - South Boston MA, US
Joseph M. Kennedy - Walpole MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US
Tiansheng Wang - Concord MA, US
M. Woods Wannamaker - Stow MA, US
Randal Byrn - Wayland MA, US
Yi Zhou - Lexington MA, US
Chao Lin - Winchester MA, US
Min Jiang - Lexington MA, US
Steven Jones - Hyde Park MA, US
Ursula A. Germann - Newton MA, US
Francesco G. Salituro - Marlborough MA, US
Ann Dak-Yee Kwong - Cambridge MA, US

International Classification:

A61K 31/506
A61K 31/55
C07D 471/04
A61K 31/553
A61K 31/5377
C07D 401/10

Abstract:

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

US Patent:

20180078553, Mar 22, 2018

Filed:

Sep 28, 2017

Appl. No.:

15/718186

Inventors:

- Boston MA, US
Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Randy S. Bethiel - Lexington MA, US
John J. Court - Littleton MA, US
Hongbo Deng - Wellesley MA, US
Ioana Davies - Arlington MA, US
John P. Duffy - Northborough MA, US
Luc J. Farmer - Montreal, CA
Huai Gao - Arlington MA, US
Wenxin Gu - Concord MA, US
Dylan H. Jacobs - South Boston MA, US
Joseph M. Kennedy - Walpole MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US
Tiansheng Wang - Concord MA, US
M. Woods Wannamaker - Stow MA, US
Randal Byrn - Wayland MA, US
Yi Zhou - Lexington MA, US
Chao Lin - Winchester MA, US
Min Jiang - Lexington MA, US
Steven Jones - Hyde Park MA, US
Ursula A. Germann - Newton MA, US
Francesco G. Salituro - Marlborough MA, US
Ann Dak-Yee Kwong - Cambridge MA, US

International Classification:

A61K 31/506

Abstract:

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

US Patent:

20170100400, Apr 13, 2017

Filed:

Oct 21, 2016

Appl. No.:

15/299757

Inventors:

- Boston MA, US
Michael P. Clark - Concord MA, US
Upul K. Bandarage - Lexington MA, US
Randy S. Bethiel - Lexington MA, US
John J. Court - Littleton MA, US
Hongbo Deng - Southborough MA, US
Ioana Davies - Arlington MA, US
John P. Duffy - Northborough MA, US
Luc J. Farmer - Montreal, CA
Huai Gao - Arlington MA, US
Wenxin Gu - Concord MA, US
Dylan H. Jacobs - South Boston MA, US
Joseph M. Kennedy - Charlestown MA, US
Mark W. Ledeboer - Acton MA, US
Brian Ledford - Norton MA, US
Francois Maltais - Tewksbury MA, US
Emanuele Perola - Brookline MA, US
Tiansheng Wang - Concord MA, US
M. Woods Wannamaker - Stow MA, US
Randal Byrn - Wayland MA, US
Yi Zhou - Lexington MA, US
Chao Lin - Winchester MA, US
Min Jiang - Lexington MA, US
Steven Jones - Hyde Park MA, US
Ursula A. Germann - Newton MA, US
Francesco G. Salituro - Marlborough MA, US
Ann Dak-Yee Kwong - Cambridge MA, US

International Classification:

A61K 31/506

Abstract:

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.